Effect of hydroxycamptothecin-based transcather arterial chemoembolization combined with hepatectomy for liver cancer
10.3760/cma.j.issn.1007-631X.2019.02.006
- VernacularTitle:羟基喜树碱化疗栓塞联合手术切除治疗肝癌的疗效分析
- Author:
Yubao SONG
1
;
Zefeng GAO
;
Zhifeng YAN
;
Yushan ZHAO
Author Information
1. 山西省肿瘤医院普外二科
- Keywords:
Carcinoma;
hepatocellular;
Antineoplastic combined chemotherapy protocols;
Camptothecin
- From:
Chinese Journal of General Surgery
2019;34(2):118-121
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate transcather arterial chemoembolization (TACE) with hydroxycamptothecin combined with hepatectomy in treatment of primary liver cancer.Methods 64 primary liver cancer cases admitted and treated in Shanxi Provincial Cancer Hospital were divided into two groups with 32 cases in each.The control group were treated by surgery only and in the study group patients received TACE and hepatectomy.Results 0.5-year and 1-year recurrence rate in the study group were respectively 9.38％ and 28.13％,significantly lower than those in the control group.There was no significant difference in the 2-year recurrence rate between the two groups.0.5-year,1-year and 2-year survival rate in the study group were respectively 93.75％,84.38％ and 65.63％,significantly better than those in the control group.The AST and ALT were respectively (86 ±42)U/L,(96 ±55)U/L which were lower than those in the control group.The ALB and TBiL were respectively (32 ± 10) g/L and (24 ± 9) μmol/L,which were not significantly different with the control group.Conlunsion Hydroxycamptothecinbased TACE combined with hepatectomy is better than hepatectomy only for the treatment of primary liver cancer.
